# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreate...
Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceu...
Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co...
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging techn...